文献速递牙周病

选择性BET抑制剂RVX-208改善牙周炎症与骨丧失

Selective BET inhibitor RVX-208 ameliorates periodontal inflammation and bone loss.
PubMed 文献 · J Clin Periodontol · 2023-10-19

本研究探讨靶向BET蛋白BD2结构域的选择性抑制剂RVX-208对牙周炎症和骨丧失的作用。体外实验显示RVX-208抑制Pg诱导的炎症基因表达与细胞因子产生,并抑制破骨细胞分化;大鼠结扎牙周炎模型中局部给予RVX-208可预防牙槽骨丧失。

要点

  • RVX-208抑制Pg感染的巨噬细胞样细胞和牙龈上皮细胞炎症反应
  • RVX-208抑制破骨细胞分化及破骨特异性基因表达
  • 局部应用RVX-208可预防大鼠实验性牙周炎牙槽骨丧失

核心结论

  • RVX-208同时调控炎症因子产生和破骨细胞分化,可能成为预防牙周炎的候选表观药物。

研究设计与样本

  • 体外使用RAW264.7巨噬细胞样细胞和人牙龈上皮细胞,经Pg刺激并给予RVX-208处理。
  • RAW264.7细胞诱导破骨分化,经RVX-208处理后评估破骨分化。
  • 大鼠采用结扎法诱导牙周炎,隔日局部给予RVX-208治疗。

主要发现

  • RVX-208抑制Pg感染细胞中炎症基因表达和细胞因子产生。
  • RVX-208减少破骨细胞数量、TRAP活性及破骨特异性基因表达。
  • 与pan-BET抑制剂JQ1相比,RVX-208对转录组的抑制更具选择性且程度更轻。
  • RVX-208局部给药预防了大鼠牙槽骨丧失。

临床怎么用

  • RVX-208作为选择性BET抑制剂,可能通过表观调控同时干预牙周炎症和骨破坏。
  • 局部给药途径在动物模型中显示预防牙槽骨丧失的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To determine the effects of RVX-208, a selective bromodomain and extra-terminal domain (BET) inhibitor targeting bromodomain 2 (BD2), on periodontal inflammation and bone loss. MATERIALS AND METHODS: Macrophage-like cells (RAW264.7) and human gingival epithelial cells were challenged by Porphyromonas gingivalis (Pg) with or without RVX-208. Inflammatory gene expression and cytokine production were measured by reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. RAW264.7 cells were induced to osteoclast differentiation. After RVX-208 treatment, osteoclast differentiation was evaluated by histology, tartrate-resistant-acid-phosphatase (TRAP) activity and the expression of osteoclast-specific genes. The effect of RVX-208 on osteoclast transcriptome was studied by RNA sequencing. Periodontitis was induced in rats by ligature and local RVX-208 treatment was administered every other day. Alveolar bone loss was measured by micro-computed tomography. RESULTS: RVX-208 inhibited inflammatory gene expression and cytokine production in Pg-infected cells. Osteoclast differentiation was inhibited by RVX-208, as evidenced by reduced osteoclast number, TRAP activity and osteoclast-specific gene expression. RVX-208 displayed a more selective and less profound suppressive impact on transcriptome compared with pan-BET inhibitor, JQ1. RVX-208 administration prevented the alveolar bone loss in vivo. CONCLUSIONS: RVX-208 regulated both upstream (inflammatory cytokine production) and downstream (osteoclast differentiation) events that lead to periodontal tissue destruction, suggesting that it may be a promising 'epi-drug' for the prevention of periodontitis.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Sun M, Clayton N, Alam S, et al. Selective BET inhibitor RVX-208 ameliorates periodontal inflammation and bone loss. J Clin Periodontol. 2023. PMID: 37855275. doi:10.1111/jcpe.13887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。